Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.37 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.36 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.36 |
| ▸ | LNPEP | Q9UIQ6 | 2/20 | 0.36 |
| ▸ | MME | P08473 | 1/20 | 0.36 |
| ▸ | CPA1 | P15085 | 2/20 | 0.36 |
| ▸ | CPA2 | P48052 | 2/20 | 0.36 |
| ▸ | CPA4 | Q9UI42 | 2/20 | 0.36 |
| ▸ | CPB1 | P15086 | 1/20 | 0.36 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6843865 | 0.85 | ACP3 (0.42) | LTA4HERAP2ERAP1LNPEP | |
| SCHEMBL7367235 | 0.84 | LTA4H (0.38) | LTA4HERAP2ERAP1LNPEPMME | |
| SCHEMBL6257526 | 0.84 | LTA4H (0.40) | LTA4HMMECPA1CPA2CPA4 | |
| SCHEMBL7386283 | 0.83 | LTA4H (0.37) | LTA4HERAP2ERAP1LNPEPMME | |
| SCHEMBL7368486 | 0.82 | LTA4H (0.36) | LTA4HERAP2ERAP1LNPEPMME | |
| SCHEMBL9351722 | 0.82 | LTA4H (0.36) | LTA4HERAP2ERAP1LNPEPMME | |
| SCHEMBL6414339 | 0.81 | ECE1 (0.39) | LTA4HERAP2ERAP1LNPEPMME | |
| SCHEMBL9352407 | 0.81 | ALDH1A1 (0.39) | LTA4H | |
| SCHEMBL9348204 | 0.80 | ECE1 (0.51) | MMEACE2 | |
| SCHEMBL6412346 | 0.79 | CPA1 (0.45) | ERAP2ERAP1LNPEPCPA1CPA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1063991-A1 | STATIN-MATRIX METALLOPROTEINASE INHIBITOR COMBINATIONS | WARNER-LAMBERT COMPANY LLC (US) | 2001-01-03 | — | — | EP | disclosed |
| EP-1047450-A1 | ACE INHIBITOR-MMP INHIBITOR COMBINATIONS | WARNER-LAMBERT COMPANY (US) | 2000-11-02 | — | — | EP | disclosed |
| EP-1028716-A1 | METHOD FOR TREATING AND PREVENTING HEART FAILURE AND VENTRICULAR DILATATION | WARNER-LAMBERT COMPANY (US) | 2000-08-23 | — | — | EP | disclosed |
| EP-0946166-A1 | USE OF MATRIX METALLOPROTEINASE INHIBITORS FOR TREATING NEUROLOGICAL DISORDERS AND PROMOTING WOUND HEALING | WARNER-LAMBERT COMPANY (US) | 1999-10-06 | — | — | EP | disclosed |
| WO-1999047138-A1 | STATIN-MATRIX METALLOPROTEINASE INHIBITOR COMBINATIONS | WARNER-LAMBERT COMPANY (US) | 1999-09-23 | — | — | WO | disclosed |
| WO-1999032150-A1 | ACE INHIBITOR-MMP INHIBITOR COMBINATIONS | WARNER-LAMBERT COMPANY (US) | 1999-07-01 | — | — | WO | disclosed |
| WO-1998026773-A1 | USE OF MATRIX METALLOPROTEINASE INHIBITORS FOR TREATING NEUROLOGICAL DISORDERS AND PROMOTING WOUND HEALING | WARNER-LAMBERT COMPANY (US) | 1998-06-25 | — | — | WO | disclosed |
| WO-1998025597-A2 | METHOD FOR TREATING AND PREVENTING HEART FAILURE AND VENTRICULAR DILATATION | WARNER-LAMBERT COMPANY (US) | 1998-06-18 | — | — | WO | disclosed |
| EP-0612324-A1 | PHOSPHONOPEPTIDES WITH COLLAGENASE INHIBITING ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 1994-08-31 | — | — | EP | disclosed |